These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

348 related items for PubMed ID: 10966531

  • 1. Rationale for the use of combination angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker therapy in heart failure.
    Carson PE.
    Am Heart J; 2000 Sep; 140(3):361-6. PubMed ID: 10966531
    [Abstract] [Full Text] [Related]

  • 2. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR.
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [Abstract] [Full Text] [Related]

  • 3. Recent changes in the landscape of combination RAS blockade.
    Epstein BJ, Smith SM, Choksi R.
    Expert Rev Cardiovasc Ther; 2009 Nov; 7(11):1373-84. PubMed ID: 19900020
    [Abstract] [Full Text] [Related]

  • 4. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [Abstract] [Full Text] [Related]

  • 5. Blocking the renin-angiotensin system: dual- versus mono-therapy.
    Ravandi A, Teo KK.
    Expert Rev Cardiovasc Ther; 2009 Jun; 7(6):667-74. PubMed ID: 19505282
    [Abstract] [Full Text] [Related]

  • 6. Suppression of the renin-angiotensin-aldosterone system in chronic heart failure: choice of agents and clinical impact.
    Jorde UP.
    Cardiol Rev; 2006 Jun; 14(2):81-7. PubMed ID: 16493245
    [Abstract] [Full Text] [Related]

  • 7. Angiotensin-converting enzyme inhibitors (ACEIs), not angiotensin receptor blockers (ARBs), are preferred and effective mode of therapy in high cardiovascular risk patients.
    Vijan SG.
    J Indian Med Assoc; 2009 Mar; 107(3):178-82. PubMed ID: 19810392
    [Abstract] [Full Text] [Related]

  • 8. Addition of an angiotensin receptor blocker to full-dose ACE-inhibition: controversial or common sense?
    van de Wal RM, van Veldhuisen DJ, van Gilst WH, Voors AA.
    Eur Heart J; 2005 Nov; 26(22):2361-7. PubMed ID: 16105846
    [Abstract] [Full Text] [Related]

  • 9. Rationale for combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor treatment and end-organ protection in patients with chronic kidney disease.
    Toto R, Palmer BF.
    Am J Nephrol; 2008 Nov; 28(3):372-80. PubMed ID: 18073461
    [Abstract] [Full Text] [Related]

  • 10. Current possibilities of ACE inhibitor and ARB combination in arterial hypertension and its complications.
    Kolasinska-Malkowska K, Filipiak KJ, Gwizdala A, Tykarski A.
    Expert Rev Cardiovasc Ther; 2008 Jun; 6(5):759-71. PubMed ID: 18510491
    [Abstract] [Full Text] [Related]

  • 11. Should angiotensin receptor blockers be added to angiotensin-converting enzyme inhibitors in the treatment of heart failure?
    Ghanem FA, Movahed A.
    Rev Cardiovasc Med; 2005 Jun; 6(4):206-13. PubMed ID: 16379016
    [Abstract] [Full Text] [Related]

  • 12. Inhibiting the renin-angiotensin system in myocardial infarction and heart failure: lessons from SAVE, VALIANT and CHARM, and other clinical trials.
    Tokmakova M, Solomon SD.
    Curr Opin Cardiol; 2006 Jul; 21(4):268-72. PubMed ID: 16755193
    [Abstract] [Full Text] [Related]

  • 13. Use of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker therapy to reduce cardiovascular events in high-risk patients: part 2.
    Bommer WJ.
    Prev Cardiol; 2008 Jul; 11(4):215-22. PubMed ID: 19476574
    [Abstract] [Full Text] [Related]

  • 14. [Blockade of the renin-angiotensin system by a combination of ACE inhibitors and AT1 receptor antagonists].
    Azizi M.
    Rev Prat; 2004 Jun 15; 54(11):1167-74. PubMed ID: 15496022
    [Abstract] [Full Text] [Related]

  • 15. Establishing a new option for target-organ protection: rationale for ARB plus ACE inhibitor combination therapy.
    Cohn JN, Goldman JM.
    Am J Hypertens; 2008 Mar 15; 21(3):248-56. PubMed ID: 18219303
    [Abstract] [Full Text] [Related]

  • 16. Heart failure: is there a role for angiotensin II receptor blockers?
    Boucher M, Ma J.
    Issues Emerg Health Technol; 2002 Sep 15; (38):1-4. PubMed ID: 12243202
    [Abstract] [Full Text] [Related]

  • 17. Cardioprotective effect of angiotensin II receptor antagonists.
    White M.
    Can J Cardiol; 1999 Nov 15; 15 Suppl F():10F-4F. PubMed ID: 10579747
    [Abstract] [Full Text] [Related]

  • 18. Angiotensin II type 1 receptor blockade: a new development in cardiovascular pharmacology.
    Leary AC, MacDonald TM.
    Int J Clin Pract; 1998 Oct 15; 52(7):475-81. PubMed ID: 10622089
    [Abstract] [Full Text] [Related]

  • 19. New opportunities in cardiovascular patient management: a survey of clinical data on the combination of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
    Weber MA.
    Am J Cardiol; 2007 Aug 06; 100(3A):45J-52J. PubMed ID: 17666198
    [Abstract] [Full Text] [Related]

  • 20. Combining renin-angiotensin-aldosterone system blockade with diuretic therapy for treatment of hypertension.
    Motwani JG.
    J Renin Angiotensin Aldosterone Syst; 2002 Jun 06; 3(2):72-8. PubMed ID: 12228846
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.